Chimerix’s Brincidofovir Selected for Use in Ebola Clinical Trial in West Africa by International Consortium

Chimerix’s Brincidofovir Selected for Use in Ebola Clinical Trial in West Africa by International Consortium

DURHAM, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) — Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that its investigational broad-spectrum antiviral brincidofovir has been selected as one of two investigational agents to be evaluated in a clinical study in patients with confirmed Ebola Virus Disease in west Africa. Chimerix and the University of Oxford are in the process of finalizing a definitive agreement for supplying brincidofovir for the planned clinical trial.